Enhancing immune response against metastatic pancreatic tumors using localized therapy
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
This study is exploring a new way to treat advanced pancreatic cancer by using a special heat treatment to target tumors and boost the immune system, helping your body fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project ID | NIH-11052594 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat metastatic pancreatic cancer by combining localized ablative immunotherapy with immune checkpoint therapy. The therapy utilizes localized photothermal treatment to destroy tumor cells, which releases tumor antigens and stimulates the immune system. By administering immunostimulants directly to the tumor site, the goal is to enhance the body's immune response, particularly the activation of T cells, to fight both the primary tumor and any distant metastases. This approach aims to overcome the limitations of conventional therapies that are often ineffective for advanced pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced-stage metastatic pancreatic cancer who have not responded well to conventional therapies.
Not a fit: Patients with early-stage pancreatic cancer or those whose tumors are resectable may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients with metastatic pancreatic cancer.
How similar studies have performed: Previous studies have shown promising results with localized immunotherapy approaches, suggesting potential for success in this novel application.
Where this research is happening
Norman, United States
- University of Oklahoma — Norman, United States (Active)
Researchers
- Principal investigator: Chen, Wei R. — University of Oklahoma
- Study coordinator: Chen, Wei R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.